

## Papua New Guinea Support for Pneumococcal Vaccine

### This Decision Letter sets out the Programme Terms

<b>1. Country:</b> Papua New Guinea				
<b>2. Grant number:</b> 1920-PNG-12c-X; 13-PNG-08a-Y				
<b>3. Date of Decision Letter:</b> 14 March 2019				
<b>4. Date of the Partnership Framework Agreement (PFA):</b> 29 November 2013				
<b>5. Programme title:</b> New Vaccine Support (NVS), Pneumococcal Routine				
<b>6. Vaccine type:</b> Pneumococcal				
<b>7. Requested product presentation and formulation of vaccine:</b> Pneumococcal (PCV13), 1 dose(s) per vial , LIQUID				
<b>8. Programme duration<sup>1</sup>:</b> 2013 -2020				
<b>9. Programme Budget (indicative):</b> (subject to the terms of the PFA, if applicable)				
	<b>2013-2018</b>	<b>2019</b>	<b>2020</b>	<b>Total<sup>2</sup></b>
Programme Budget (US\$)	9,369,797 <sup>3</sup>	-	388,000	9,757,797
<b>Vaccine introduction grant (in US\$):</b> Net amount of \$180,852 disbursed 22 July 2013				
<b>10. Indicative Annual Amounts:</b> (subject to the terms of the PFA, if applicable) <sup>4</sup>				
<b>Type of supplies to be purchased with Gavi funds in each year</b>	<b>2013-2018</b>	<b>2019</b>		
Number of Pneumococcal vaccines doses		-		
Annual Amounts (US\$)	9,369,797 <sup>5</sup>	-		
<b>11. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.				
<b>12. Self-procurement:</b> Not applicable.				

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

**13. Co-financing obligations:** Reference code: 1920-PNG-12c-X-C

According to the co-financing policy, the Country falls within the group Accelerated Transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2019	2020
Number of vaccine doses	-	577,400
Number of AD syringes	-	635,100
Number of re-constitution syringes	-	-
Number of safety boxes	-	7,000
Value of vaccine doses (US\$)	-	1,905,118
Total co-financing payments (US\$) (incl. freight)	-	1,997,000

**14. Operational support for campaigns:** Not applicable

**15. Additional reporting requirements:** Not applicable

	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> <li>Vaccine stock levels including buffer stock, by end March;</li> <li>Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	31 March 2019 15 May 2019
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

**16. Financial clarifications:** Not applicable.

**17. Other conditions:** Not applicable.

Signed by,



**On behalf of Gavi**

Hind Khatib-Othman  
Managing Director, Country Programmes  
14 March 2019